DUBLIN--(BUSINESS WIRE)--The "Plasma Fractionation Market by Product (IVIG, Albumin, Factor VIII, von Willebrand Factor, PCC, Protease Inhibitor), Application (Immunology, Hematology, Critical Care, Rheumatology), End User - Global Forecast to 2023" report has been added to ResearchAndMarkets.com's offering
The plasma fractionation market is projected to reach to USD 29.50 billion by 2023 from an estimated USD 21.23 billion in 2018.
The growing geriatric population across the globe, increasing use of immunoglobulins in various therapeutic areas, growing prevalence of respiratory diseases and uptake of alpha-1-antitrypsin, and increase in plasma collection are the factors driving this market. However, the emergence of recombinant alternatives, high cost of plasma products, and limited reimbursement may hinder the growth of this market.
On the basis of product, the plasma fractionation market is segmented into immunoglobulins, coagulation factor concentrates, albumin, protease inhibitors, and other plasma products. The protease inhibitors segment is expected to witness the highest growth during the forecast period. The high growth of this segment is primarily attributed to the increasing prevalence of alpha-1 antitrypsin deficiency and increasing number of various respiratory diseases.
Based on the application, the plasma fractionation market is classified into neurology, immunology, hematology, critical care, pulmonology, hemato-oncology, rheumatology, and other applications. The pulmonology segment is expected to grow at the highest CAGR during the forecast period. This can largely be attributed to the increasing use of immunoglobulins and protease inhibitors in the treatment of various respiratory diseases such as AATD and COPD, asthma, and respiratory tract infections.
On the basis of type of end user, the market is segmented into hospitals & clinics, clinical research laboratories, and academic institutes. During the forecast period, the hospitals & clinics segment is expected to grow at the highest CAGR. The high growth of this segment can be attributed to the increasing adoption of plasma products in the treatment of various immunological, neurological, and bleeding disorders; large patient pool treated in hospitals; growing number of hospitals & clinics across the globe; and increasing number of collaborations between the manufacturers of plasma products and hospitals.
Asia Pacific is expected to witness the highest growth during the forecast period (2018 to 2023). The region's large geriatric population, large population, improving healthcare infrastructure, increasing incidences of immunological and bleeding diseases, increasing focus diagnosis and prophylactic treatment, and increasing awareness about technologically advanced products are driving the growth of this market.
Some of the major market players in the plasma fractionation market are CSL (Australia), Grifols (Spain), Shire (Ireland), Octapharma (Switzerland), Kedrion (Italy), Bio Product Laboratory (UK), Sanquin (Netherlands), LFB (France), Biotest (Germany), Japan Blood Products Organization, China Biologic Products (China), Green Cross Corporation (South Korea), and Shanghai RAAS Blood Products (China).
Key Topics Covered:
2 Research Methodology
3 Executive Summary
4 Premium Insights
5 Market Overview
6 Industry Insights
7 Plasma Fractionation Market, By Product
8 Plasma Fractionation Market, By Application
9 Plasma Fractionation Market, By End User
10 Geographic Analysis
11 Competitive Landscape
12 Company Profiles
- Beijing Tiantan Biological Products
- Bio Product Laboratory (BPL)
- China Biologic Product
- Green Cross Corporation
- Japan Blood Products Organization
- Shanghai RAAS Blood Products
For more information about this report visit https://www.researchandmarkets.com/research/42llxm/plasma?w=4